Results 271 to 280 of about 720,989 (310)
Some of the next articles are maybe not open access.
Immunotoxins against solid tumors
Journal of Cancer Research and Clinical Oncology, 1988Antibody-toxin conjugates, termed immunotoxins, are currently being evaluated as potential new anticancer agents. The monoclonal antibodies that recognize antigens on the surface of tumor cells should deliver the toxins or the catalytic subunits of toxins to cancer cells.
openaire +2 more sources
Autotransplantation in solid tumors
Blood Reviews, 1991Studies are described of high-dose therapy in metastatic breast cancer, early stage breast cancer, stage IV neuroblastoma, recurrent or bulky disease testicular cancer and Ewing's sarcoma. The outcome in these subgroups with conventional therapy is described for comparison.
openaire +2 more sources
Cancer Genetics and Cytogenetics, 1988
Abstract Nonrandom chromosome rearrangements have been identified in solid tumors. These rearrangements involve malignant solid tumors and benign tumors such as lipomas and uterine leiomyomata. To aid research, specific and additional chromosome rearrangements in solid tumors are listed by breakpoint.
openaire +2 more sources
Abstract Nonrandom chromosome rearrangements have been identified in solid tumors. These rearrangements involve malignant solid tumors and benign tumors such as lipomas and uterine leiomyomata. To aid research, specific and additional chromosome rearrangements in solid tumors are listed by breakpoint.
openaire +2 more sources
Clinical studies: Solid tumors
1988Immunotoxins (ITs) permit delivery of a therapy at the tumor site specifically. The use of ITs as therapy of patients with solid tumors presents problems which require unique solutions. These include stability in vivo, cellular heterogeneity, access to tumor, biodistribution, and the immune response to the immunoconjugate (Table 1).
openaire +2 more sources
Therapy-associated Solid Tumors
Acta Oncologica, 2002As survival after a diagnosis of cancer improves, characterization of the late sequelae of treatment becomes critical. The development of second malignant neoplasms represents one of the most serious side effects of treatment with radiation and chemotherapy.
openaire +2 more sources
Surgical Clinics of North America, 1979
The concept of immunotherapy has evolved into a multifaceted and specialized concern. Nonspecific immunotherapy, for example, refers to the use of substances that randomly stimulate the host-immune response. Specific immunotherapy, in contrast, is intended to evoke a particular immune response against tumor antigens.
openaire +2 more sources
The concept of immunotherapy has evolved into a multifaceted and specialized concern. Nonspecific immunotherapy, for example, refers to the use of substances that randomly stimulate the host-immune response. Specific immunotherapy, in contrast, is intended to evoke a particular immune response against tumor antigens.
openaire +2 more sources
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Ca-A Cancer Journal for Clinicians, 2021Michael L Cheng +2 more
exaly
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Current and future cancer staging after neoadjuvant treatment for solid tumors
Ca-A Cancer Journal for Clinicians, 2021James D Brierley Mb, Frcp +1 more
exaly